PP-US-IRON-0028 10/17
Daiichi Sankyo, Inc., are the marketers of Injectafer. Injectafer® (ferric
carboxymaltose injection) is an iron replacement product indicated for the
treatment of iron deficiency anemia (IDA) in adult patients who have
intolerance to oral iron or have had unsatisfactory response to oral iron, and in
adult patients with non-dialysis dependent chronic kidney disease. Injectafer is
not approved to treat the symptoms of Iron Deficiency Anemia and is not
indicated to improve functional status and quality of life. Additionally, the dosing
of Injectafer as indicated in appropriate patients is up to 750 mg per dose with 2
doses per course. If you have any questions or concerns, please contact American
Regent Medical Affairs at: (888) 354-4855.
The uses described in the enclosed information have not been approved or
cleared by FDA, as applicable to Injectafer. This information is being
provided in response to your request;
The Summary of the 2017 ACC/AHA/HFSA Focused Update of the 2013
ACCF/AHA Guidelines for the Management of Heart Failure were published
by the AHA-ACC and Guideline Central. Daiichi Sankyo, Inc. has no vested
interest in the creation of this summary;
Please note, the enclosed is a summary of the 2017 ACC/AHA/HFSA
Focused Update of the 2013 ACCF/AHA Guidelines for the Management of
Heart Failure. For the full focused update to the guidelines, please visit
http://circ.ahajournals.org/content/136/6/e137
